| Abbvie (3) |  |
| Alkaloid (11) | |
| Allergan (6) | |
| Astrazeneca (7) | |
| Basi (302) | |
| Bayer (10) | |
| Eisai company (3) | |
| Emergent biosolutions (4) | |
| F hoffmann la roche ltd (24) | |
| Glaxosmithkline (15) | |
| Merck & co (4) | |
| Novartis (22) | |
| Pfizer (10) | |
| Regeneron pharmaceuticals (3) | |
| Sanofi (5) | |
the company immediately added Abbvie Viekira Pak to its National Preferred Formulary as the exclusive option for patients with genotype 1 hepatitis Cust three days after the FDA approved the drug.
Abbvie agreed to an undisclosed lower price for Viekira Pak, which lists at $83, 319 per 12-week course.
Express Scripts pursued talks with Abbvie after failing to reach agreement with Gilead on a discount for Sovaldi
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011